A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).

Purpose: We report a phase II clinical study of the combination of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in platinum- and taxane-resistant recurrent ovarian cancer, based on the recommended doses determined in a phase I trial.

Methods: PLD was administered intravenously at a dose of 30 mg/m on day 3. CPT-11 was administered intravenously at a dose of 80 mg/m on days 1 and 15, according to the recommendations of the phase I study.